Clinical trial / 2019
Metformin blunts gains in lean body mass and thigh muscle mass from progressive resistance exercise training in healthy older adults.
In the MASTERS trial, healthy adults aged 65 and older performed 14 weeks of supervised progressive resistance training (PRT) while receiving either 1,700 mg/day metformin (N = 46) or placebo (N = 48). Placebo gained more lean body mass (p = .003) and thigh muscle mass (p < .001) than metformin. Increases in thigh muscle area (p = .005) and density (p = .020) were also greater in placebo compared with metformin, alongside a non-statistically significant trend for blunted strength gains in the metformin group. Metformin increased AMPK signaling and showed a trend for blunted mTORC1 signaling increases in response to PRT.
- Study type
- Randomized, double-blind, placebo-controlled multicenter trial
- Who was studied
- Healthy women and men aged 65 and older (N = 46 metformin, N = 48 placebo)
- What was measured
- Lean body mass, thigh muscle mass, thigh muscle area and density, strength gains, and muscle biopsy characteristics following 14 weeks of progressive resistance training
THE PAPER
Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A randomized, double-blind, placebo-controlled, multicenter trial: The MASTERS trial.
Walton RG, Dungan CM, Long DE, Tuggle SC, Kosmac K, Peck BD, Bush HM, Villasante Tezanos AG, McGwin G, Windham ST, Ovalle F, Bamman MM, Kern PA, Peterson CA. Aging Cell, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.